Pulmonary fungal infection
Conditions
Interventions
trial group:Aerosol inhalation of amphotericin B combined with primary prevention
control group:primary prevention
Sponsors
The First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18-75 years old; 2. Gender: male or female; 3. Patients with hematological malignancies receiving chemotherapy (1) Newly diagnosed acute myeloid leukemia / myelodysplastic syndrome (AML / MDS): initial diagnosis with granulocytopenia ; or induction therapy predicts agranulocytosis for more than 10 days; (2) The patients with AML / MDS / ALL aged over 65 years were treated with chemotherapy; (3) Patients with relapsed or refractory AML / MDS / ALL received salvage chemotherapy. 4. Patients after hematopoietic stem cell transplantation: (1) Patients with grade III - IV acute GVHD after transplantation are expected to receive methylprednisolone >= 2mg / kg for more than one week; (2) Persistent agranulocytosis due to chemoradiotherapy or cellular immunotherapy after transplantation is expected to be more than one week. 5. Patients with severe aplastic anemia receiving ATG / ALG intensive immunotherapy.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating women; 2. ECOG score >= 3; 3. Severe cardiopulmonary insufficiency; 4. Allergic to amphotericin B antifungal drugs; 5. Dyspnea.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of fungal infection; | — |
Secondary
| Measure | Time frame |
|---|---|
| Attributable mortality; | — |
Countries
China
Contacts
Public ContactDepei Wu
The First Affiliated Hospital of Soochow University
Outcome results
None listed